smartQare’s Post

Exciting news for #Cardiology ! ❤️ A recent study at St. Antonius Hospital Nieuwegein, The Netherlands illustrated real-world implementation of #CYP2C19 genotype-guided #P2Y12 inhibitor treatment for acute coronary syndrome (ACS) patients. 🔗Read the full article below! 🧬Learn more about the FDA cleared and CE marked Genomadix CYP2C19 test used in this study at www.genomadix.com! #GenomadixCube #startups #qpcr #biotechnology #moleculardiagnostics #diagnostics #genotyping #genetictesting #healthcare #precisionmedicine #precisionhealth #Pharmacogenetics #Pharmacogenomics #PGx #PGxmovement #neurology #cardiology #stroke #StrokeAwareness #StrokePrevention #OptimizedDAPT #DAPT #AntiplateletTherapy #ticagrelor #prasugrel #clopidogrel #antiplatelet #P2Y12 #CYP2C19 #ACS #PCI

We are beyond excited to announce the official start of an extensive research collaboration with Acibadem City Clinic Cardiovascular Center! Together we aim to improve the global standard of vascular care by timely diagnosis of Peripheral Arterial Disease (PAD), based on Kelvin Health's unique combination of mobile thermography & visual AI. Honored to have prof. Ivo Petrov as a Principal Investigator of the study. To celebrate this, we share a throwback to a series of Q&A videos with him explaining why is he so positively moved by the impact our solution will make to patients with PAD: 👉 Social impact, on both patients and healthcare systems - https://lnkd.in/d-T9YD44 👉 A thermal picture captured and analyzed with Kelvin Health “worths a thousand words” - https://lnkd.in/dg4kuk_p 👉 The importance of follow-up when performing more than 1 000 endovascular procedures - https://lnkd.in/dq8gRd-4 👉 Rapid triage that can give a proper start of the patient journey - https://lnkd.in/daqAXgRV 👉 One of the most emotional cases in his practice with Kelvin Health at the time - https://lnkd.in/d7tA83Kz 👉 Optimizing the process to be extremely patient-friendly - https://lnkd.in/dUd59t9g 👉 Breakthrough in diagnostics of vascular diseases via thermography today, after decades of existence - https://lnkd.in/dQW4QzQ3 👉 Empowering even the non-specialist to screen and triage rapidly and effortlessly - https://lnkd.in/dNXj8PnD 👉 Help protect the health and the lives of the patients in their most critical moments - https://lnkd.in/d7rAfYDT 👉 Observations about the performance of Kelvin Health - https://lnkd.in/dHemiQNT 👉 The therapeutic areas, other than vascular pathology, where Kelvin Health can have huge positive impact - https://lnkd.in/dUf9Y5d4

#ARVO2024 Update 28: Defocus Incorporated Multiple Segment lenses and 0.025% atropine for myopia control in a European population: 12-month results of a randomized clinical trial. Noemi Guemes-Villahoz from Hospital Clinico San Carlos, Spain, and co-authors. This randomized controlled trial compared the efficacy of combination treatments 0.025% atropine and DIMS lenses with 0.025% atropine and single vision (SV) lenses in slowing myopia progression in European myopic children (n=56) aged 4-16 years over 12 months. Combination treatment with 0.025% atropine and DIMS lenses were more effective than 0.025% atropine and SV lenses in controlling axial elongation, with only 0.07mm growth over 12 months in the combo group compared to 0.20mm in the (slightly younger) atropine group. Definitive data on whether adding 0.05% atropine boosts DIMS efficacy would require comparison to a DIMS monotherapy group, but the small absolute growth indicates a possible synergistic effect. Abstract link: https://lnkd.in/gnxPWKmd Pictured: a busy exhibitor session in the Exhibition Hall, image by ARVO. #myopia #myopiacontrol #myopiamanagement #professionallearning #research

Movano Evie Ring to be used in MIT Long Covid study By James Stables Despite a lukewarm reception and our own misgivings in our initial Evie Ring review, the smart ring will be used to track the vitals of patients with long COVID and chronic Lyme disease. “We’re excited to incorporate the Evie Ring into our clinical study to evaluate the progression of long COVID and chronic Lyme disease and paint a fuller picture of why some people bounce back from a mild infection while others go on to endure prolonged suffering,” said Dr Michal Caspi Tal, associate scientific director at the MIT Center for Gynepathology Research and head of the Tal Research Group, said in a statement. “The breadth of longitudinal information related to vital signs and wellness provided by the ring will be instrumental in enhancing our understanding of these debilitating conditions.” In our initial conversations with John Mastrototaro, CEO of Movano, he told Wareable that it was a key ambition of the company for Evie to be used in medical settings. While it’s still waiting for clearance, the company aims to have all of its sensors and metrics FDA cleared – even ‘basic’ ones such as heart rate and SpO2. It’s rare for device makers to go down this route because most claim that their devices are ‘not for medical use.’ We’ve recently published our early Movano Evie Ring, which has been beset by technical issues and complaints around the basic nature of the features and insights. But MIT selecting Evie is a vote of confidence in the accuracy of its sensors, which has not been a cause for concern. Our criticisms of the ring stemmed from reliability issues, and the basic nature of its insights. It also validates Movano’s strategy for Evie to be used outside of the consumer setting. Success in this area will enable the company to keep offering the ring without a subscription, and keep prices down. Now it just needs to hunker down and ensure that its consumer experience can rival the likes of Oura. Posted by Larry Cole - my usual disclaimers at in play here. I was not asked to post this MIT piece, nor do I know anyone at Movano. I do these as public interest stories more than anything else. If you follow my posts you will already know I am a big believer in wearables fundementally changing how we deliver healthcare to the masses.

🌟 Exciting Insight in TAVR Practice: No Immediate CAD Treatment Required Before TAVR 🚀 At ArchCath, we're committed to sharing groundbreaking developments in cardiac care, aligning with our mission to advance TAVR procedures. Today, we're thrilled to spotlight a significant revelation brought forth by recent observational data, shedding new light on managing coronary artery disease (CAD) in patients undergoing TAVR. 🔍 Key Findings: Highlighted in a study published in the European Heart Journal, these findings challenge the traditional approach to CAD treatment pre-TAVR. Led by Dr. Rishi Puri from the Cleveland Clinic, the study examined nearly 2,000 patients, revealing compelling evidence: patients with obstructive CAD, including those with high- and extreme-risk disease, may not require immediate intervention before TAVR. Surprisingly, no significant disparities were observed in all-cause mortality or major adverse cardiovascular events between patients with and without coronary lesions. 💡 Implications: This groundbreaking insight suggests that embracing a TAVR-first strategy, prioritizing TAVR as the initial intervention, and addressing CAD subsequently could offer substantial benefits. Esteemed experts like Dr. Rodrigo Bagur from Western University/London Health Sciences Centre and Dr. David Wood from the University of British Columbia/Vancouver General Hospital endorse this approach, citing its potential to enhance patient outcomes and streamline care pathways. 📈 Future Directions: As we continue to navigate the frontier of cardiac innovation, it's imperative to embrace evidence-based practices that optimize patient care and outcomes. Stay tuned to ArchCath's LinkedIn page for further updates on TAVR advancements and breakthroughs in cardiovascular health! 🔗 Original Study: For more insights into this study, access the original article here:  https://lnkd.in/dByTX9t7 #ArchCath #TAVR #CoronaryArteryDisease #Innovation #CardiacCare #Healthcare #MedicalAdvancements

🔬 Research News: We’re excited to share the latest results from our prospective study on late-onset giant cell arteritis (GCA) in patients initially diagnosed with polymyalgia rheumatica (PMR)! Our research explored the incidence of late-onset GCA within the first year of PMR diagnosis using repeated FDG-PET/CT scans and vascular ultrasonography. This is the first study to use repeated imaging to exclude GCA at baseline and diagnose it during follow-up. 📊🩺 Key Findings: A low incidence of late-onset GCA, with only 2 out of 62 patients (3%) developing it, translating to an incidence rate of 32 cases per 1000 person-years. 📉 Low prevalence of subclinical GCA, with only 2 out of 64 cases (3%) identified at baseline in a rapid referral clinic for suspected PMR patients. 🏥 These findings offer valuable insights into the use of imaging for diagnosing and monitoring subclinical GCA in PMR patients. For more details, read the full study: https://lnkd.in/dH6CdJgC Andreas Wiggers Nielsen, Ellen-Margrethe Hauge, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Kjær, Jesper Blegvad-Nissen, Kate Rewers, Christian Møller Sørensen, Lars Christian Gormsen, Kresten Krarup Keller #Research #Healthcare #GiantCellArteritis #PolymyalgiaRheumatica #MedicalImaging #Innovation

Congratulations to Dr. Sukesh Burjonroppa, Dr. Richard Vigness and the entire Texas Health Fort Worth Texas Health Resources structural heart team for their recent success in completing the first BASILICA procedure in Tarrant County! What better time than "heart month" to mark this significant milestone. This breakthrough procedure provides a new treatment option for patients who have higher risk for coronary artery obstruction during Transcatheter Aortic Valve Replacement (TAVR) relating to their unique anatomy. When someone undergoes TAVR evaluation, scans may show the existing aortic valve has especially long leaflets - the flaps that open and close with each heartbeat; or the coronary arteries may sit unusually close to the aortic valve. During TAVR, the replacement valve may then push the existing leaflets into the coronary arteries causing a blockage - a rare but potentially fatal complication. But with BASILICA (Bioprosthetic Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction during TAVR), doctors use a tiny electrified wire to slice and push aside existing valve flaps, thereby avoiding the risk of coronary artery obstruction. "This is a niche procedure for a small subset of our patient population," explains Dr. Burjonroppa. "But there would be significant obstruction if that leaflet was not removed. By doing this, we make sure there is an adequate opening for blood flow. For this particular patient it was a great procedure. She's feeling like a million bucks - no more shortness of breath! This is another tool in the toolbox to provide exceptional care." To learn more, call our Texas Health Fort Worth Structural Heart Clinic at (817) 250-8287.

Just recently the German Federal Cabinet passes the ‘Healthy Heart Act’, paving the way for the successful #VRONIstudy from Bavaria for the early 🔎 detection of familial hypercholesterolaemia (#FH). This 🏁 major achievement was once initiated by the Bavarian #flagshipproject #DigiMedBayern for a medicine of the future and further achievements in projects on #cardiovasculardisease resulting from DigiMed will be presented this fall at the “𝗗𝗶𝗴𝗶𝗠𝗲𝗱 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟰: 𝗕𝗶𝗴 𝗱𝗮𝘁𝗮 𝗳𝗿𝗼𝗺 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 – 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝘁𝗼 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱, 𝗽𝗿𝗲𝘃𝗲𝗻𝘁 𝗮𝗻𝗱 𝗰𝘂𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲?” 📅 on 6 November 📍at the TranslaTUM of TUM Universitätsklinikum Klinikum rechts der Isar in Munich! Register here: ➡️ https://lnkd.in/eky7JHrN Dr. veronika sanin, cardiologist, lipidologist, and preventive medicine specialist in the lipid clinic at the Deutsches Herzzentrum München since 2014, was the principal leader of the #VRONI study. She will give her view on “A vision with care: The VRONI study on familial hypercholesterinemia”. 🔉 She says “Early Action, lifelong impact: early detection and treatment in Familial Hypercholesterolemia are crucial!” Dr. Sanin will be one of several speakers in the session “Information-based cardiovascular #medicalcare” with more great insights of further experts as there are: Dr. med. Fabian Starnecker (Technische Universität München), Dr. Lara Marie Reimer (Universitätsklinikum Bonn), Prof. Dr. med. Lars Maegdefessel (TUM University Hospital) and Dr. med. Dr. med. Moritz von Scheidt (Deutsches Herzzentrum München/TUM University Hospital). The subsequent scientific panel discussion with audience and speakers on “Better healthcare with DigiMed Bayern-like approaches?” is going to be very exciting! Don’t miss that! #DigiMedBayernSymposium #DMS2024 #DigitalHealthSummit #DHS2024 #DigitalHealth #cardiovasculardisease #cardiology #multiomics #healthdata #ArtificalIntelligence

𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗣𝗮𝗿𝗮𝗱𝗶𝗴𝗺 𝗳𝗼𝗿 𝗛𝗲𝗮𝗿𝘁 𝗙𝗮𝗶𝗹𝘂𝗿𝗲 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 Our pilot study, which evaluated Physician directed, Patient Self Management (#PSM) paradigm using Left Atrial Pressure (#LAP), was just published at the European Journal of Heart Failure (EJHF). 📈 With these promising findings, we will continue to advance innovative, patient-focused, heart failure treatments that transform disease management at scale. 🙏 A huge thank you to the dedicated teams at all participating study sites, Vectorious team, and our invaluable partners for making this possible. https://lnkd.in/dXw4Y-ZP Leor Perl tal hasin levan kurashvili Dr. Sebastian Feickert Manhal Habib Oren Caspi Michael Jonas Ignacio J Amat Santos Antoni Bayes-Genis Pau Codina Verdaguer Oran Koren Shir Frydman Rachel M. Pachino Stefan Anker William Abraham Dedi Erdheim Eyal Orion, MD #medtech #heartfailure #EJHF

The future of heart failure management